AbbVie Inc. logo

AbbVie Inc. (ABBV)

Market Open
12 Aug, 17:29
NYSE NYSE
$
247. 43
-2.66
-1.0636%
$
434.7B Market Cap
42.2 P/E Ratio
1.58% Div Yield
106,530 Volume
10.28 Eps
$ 250.09
Previous Close
Add Transaction
Day Range
245.52 250.09
Year Range
190.75 267.47
Want to track ABBV and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
2 Dividend Stocks to Buy Hand Over Fist in April

2 Dividend Stocks to Buy Hand Over Fist in April

One factor that keeps some investors away from healthcare stocks is the sector's dearth of generous and reliable dividend payers. This stands to reason, as nearly every stage of drug development and marketing is resource- and capital-intensive, and as a result, cash can be in short supply.

Fool | 1 year ago
3 High-Yielding Dividend Stocks That Retirees Can Buy and Forget About

3 High-Yielding Dividend Stocks That Retirees Can Buy and Forget About

"Buy and hold" is a simple strategy for investors, but it can be a hard one to stick to in actual practice. That's because many people want to pick stocks and trade them, and feel like they need to actively intervene to generate significant gains.

Fool | 1 year ago
AbbVie Stock Rises 16% Year to Date: Time to Buy, Sell or Hold?

AbbVie Stock Rises 16% Year to Date: Time to Buy, Sell or Hold?

Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.

Zacks | 1 year ago
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks

Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks

Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'

Cnbc | 1 year ago
Best Dividend Aristocrats For April 2025

Best Dividend Aristocrats For April 2025

Dividend Aristocrats are outperforming the S&P 500 in 2025, demonstrating resilience, with NOBL up 1.78% YTD versus SPY's 4.9% decline. Top performers include Consolidated Edison (+22.98%), Brown & Brown (+20.65%), and AbbVie (+16.61%), showcasing strong double-digit gains. 29 out of 69 Dividend Aristocrats have announced dividend increases in 2025, with an average growth rate of 4.15%.

Seekingalpha | 1 year ago
AbbVie: Margin Expansion Potential Can Support Elevated P/E

AbbVie: Margin Expansion Potential Can Support Elevated P/E

I don't see an obvious bias in AbbVie Inc.'s risk/return ratio. But I see it as a solid hold under current conditions. The company is grappling with diminishing Humira sales and is also trading at an above-average P/E. However, I see a potential profit margin expansion and also a healthy EPS growth ahead due to many catalysts.

Seekingalpha | 1 year ago
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.

Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.

Building a retirement portfolio of $1 million or more is within reach for many Americans. The primary things you'll need are time and money to invest.

Fool | 1 year ago
Top 4 defensive stocks to buy and hold ahead of Liberation Day

Top 4 defensive stocks to buy and hold ahead of Liberation Day

American stocks have crashed this year as concerns about Donald Trump tariffs rose. The top blue-chip indices like the Dow Jones, Nasdaq 100, and S&P 500 have all moved into a correction as recession odds have soared.

Invezz | 1 year ago
3 Relatively Safe Stocks to Buy Right Now

3 Relatively Safe Stocks to Buy Right Now

Investing in stocks comes with risks. There's no way around that fact.

Fool | 1 year ago
AbbVie Vs. Sanofi: Which Is The Better Investment Right Now

AbbVie Vs. Sanofi: Which Is The Better Investment Right Now

AbbVie and Sanofi occupy leading positions in the global immunology market. Each of them has advantages, as well as dark spots in the pipeline of drugs relative to the rival. In this article you will discover whether Sanofi or AbbVie is a more promising stock in the long term.

Seekingalpha | 1 year ago
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

Zacks | 1 year ago
2 Dividend Stocks Defying the Market Dip to Buy for a Lifetime of Passive Income

2 Dividend Stocks Defying the Market Dip to Buy for a Lifetime of Passive Income

Equities haven't performed well this year due to a combination of factors. Macroeconomic tensions are at the top of that list.

Fool | 1 year ago
Loading...
Load More